Cours Diaxonhit Euronext Paris
Actions
FR0004054427
Recherche biotechnologique et médicale
CA 2023 | 130 M 140 M 127 M | CA 2024 * | 138 M 149 M 135 M | Capitalisation | 151 M 163 M 147 M |
---|---|---|---|---|---|
Résultat net 2023 | 4 M 4,31 M 3,9 M | Résultat net 2024 * | 9 M 9,69 M 8,78 M | VE / CA 2023 | 1,29 x |
Dette nette 2023 * | 23 M 24,77 M 22,45 M | Trésorerie nette 2024 * | 9,9 M 10,66 M 9,66 M | VE / CA 2024 * | 1,02 x |
PER 2023 |
38,3
x | PER 2024 * |
15,6
x | Employés | - |
Rendement 2023 * |
-
| Rendement 2024 * |
-
| Flottant | 61,3% |
Dirigeants | Titre | Age | Depuis |
---|---|---|---|
Denis Fortier
CEO | Chief Executive Officer | - | 19/06/17 |
Director of Finance/CFO | 43 | 01/10/22 | |
Cathie Marsais
COO | Chief Operating Officer | - | - |
Administrateurs | Titre | Age | Depuis |
---|---|---|---|
Denis Fortier
CEO | Chief Executive Officer | - | 19/06/17 |
Director/Board Member | 68 | 04/11/09 | |
Director/Board Member | 67 | 15/06/17 |
Varia. 1 janv. | Capi. | |
---|---|---|
+17,96% | 44,96 Md | |
+1,17% | 42,65 Md | |
+48,77% | 41,85 Md | |
-4,27% | 29,04 Md | |
+11,42% | 26,08 Md | |
-21,39% | 19,03 Md | |
+4,86% | 12,75 Md | |
+27,29% | 12,06 Md | |
-3,50% | 11,75 Md |